On October 6, 2017, the subscription period for ADDvise Group AB (publ) (“ADDvise” or the “Company”) bond issuance ended. The original offer amounted to 100 MSEK with a bond limit of up to 240 MSEK (the ”Offer”). Due to the oversubscription of the Offer, the Board of Directors decided to exercise its right to issue and assign bonds totalling 120 MSEK. In total, subscriptions of approximately 133 MSEK were received from 2,093 number of investors.
First day of trading has been decided to be October 13, 2017.
The Offer in brief
• The bonds have a maturity of 5 years and the bond loan will be repaid in October 2022.
• The bonds run at a fixed annual nominal interest rate of 7.25 per cent. Interest is paid quarterly in arrears.
• Collateral for the bond are shares in the subsidiaries Hettich Labinstrument AB and Surgical Tables Inc.
Trade Identification and ISIN code
The trade name of the bonds will be ADDVISE 002 and the bond’s ISIN code is SE0010298166
Financial and legal advisors
Avanza Bank and Mangold Fondkommission are the financial advisors and Baker McKenzie is the legal advisors to ADDvise Group.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on October 10, 2017 at 16:30 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.